Highlighting research presented at the Infectious Diseases Week (IDWeek) annual congress, Brighton, UK-based biotech Destiny Pharma (AIM: DEST) says there is “strong support” for the use of its XF-73 nasal product.
The infectious diseases specialist is developing the ultra-rapid bactericidal, which has a novel mechanism of action, as an alternative to mupirocin.
In Phase IV research presented at IDWeek, the relationship between staphylococcus aureus decolonization and intensive care unit (ICU) infection rates was explored.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze